MINERALYS THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.36 USD | +1.64% |
|
-4.26% | +43.72% |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 604M |
|---|---|---|---|---|---|
| Net income 2024 * | -142M | Net income 2025 * | -173M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 105M | Net cash position 2025 * | 137M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-4.06
x | P/E ratio 2025 * |
-3.79
x | Employees | 28 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.47% |
More Fundamentals
* Assessed data
More news
Latest transcript on Mineralys Therapeutics, Inc.
More recommendations
More press releases
| 1 day | -0.33% | ||
| 1 week | -5.81% | ||
| Current month | -0.73% | ||
| 1 month | +2.44% | ||
| 3 months | -17.50% | ||
| 6 months | +82.86% | ||
| Current year | +41.40% |
1 week
11.69
12.55
1 month
11.6915.00
Current year
7.9516.91
1 year
5.8517.44
3 years
5.8521.98
5 years
5.8521.98
10 years
5.8521.98
| Managers | Title | Age | Since |
|---|---|---|---|
Jon Congleton
CEO | Chief Executive Officer | 60 | 20-10-31 |
Adam Levy
DFI | Director of Finance/CFO | 46 | 22-02-28 |
Jessica Ibbitson
CTO | Chief Tech/Sci/R&D Officer | - | 21-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 56 | 21-01-31 | |
Glenn Sblendorio
BRD | Director/Board Member | 68 | 23-09-12 |
Daphne Karydas
BRD | Director/Board Member | 49 | 23-09-12 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +4.49% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-29 | 12.31 | +1.23% | 61,077 |
| 24-05-28 | 12.16 | -0.33% | 82,538 |
| 24-05-24 | 12.2 | -0.25% | 44,910 |
| 24-05-23 | 12.23 | -2.32% | 69,348 |
| 24-05-22 | 12.52 | -3.02% | 44,436 |
Delayed Quote Nasdaq, May 28, 2024 at 04:00 pm EDT
More quotes
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone. The Companyâs product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is initially developing for the treatment of patients with uncontrolled hypertension (uHTN). Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. The Company completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uHTN. In addition to hypertension, the Company intends to develop lorundrostat for the treatment of chronic kidney disease (CKD).
Calendar
2024-08-04
- Q2 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
12.16
USD
Average target price
33.5
USD
Spread / Average Target
+175.49%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +41.40% | 604M | |
| +54.05% | 58.71B | |
| -2.02% | 41.31B | |
| +37.52% | 39.2B | |
| -10.22% | 27.4B | |
| +13.42% | 26.55B | |
| -21.60% | 18.98B | |
| +2.89% | 12.51B | |
| +22.40% | 11.94B | |
| +27.49% | 12.08B |
- Stock Market
- Equities
- MLYS Stock
